CA
CARL.KL
—
Bursa Malaysia
Diversified Medical Equipment & Supplies
Carlo Rino Group Bhd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
9,76 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
223
Day range
$11,72–$12,07
Prev close
$11,89
Open
$11,90
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Carlo Rino Group Bhd operates in the apparel and accessories retail sector, primarily generating revenue through the sale of fashion products to consumers in Malaysia and potentially other regional markets.
Business. Carlo Rino Group Bhd (CARL.KL) is a diversified medical equipment and supplies company listed on Bursa Malaysia. The firm operates within the health care sector, focusing on the sale of medical products. Specific details regarding its operating segments and geographic presence are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY5 analysts
5 buy0 hold0 sell
Avg 12m price target19,00
Analyst recommendations
5 analysts · consensus BuyBuy5
Hold0
Sell0
12-month price target
19,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CARL.KL. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Carlo Rino Group Bhd (CARL.KL) is a diversified medical equipment and supplies company listed on Bursa Malaysia. The firm operates within the health care sector, focusing on the sale of medical products. Specific details regarding its operating segments and geographic presence are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
AI synthesis
GENERATEDCarlo Rino Group Bhd has a fully diluted share count of 488,758,548 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. The absence of liquidity metrics and balance-sheet inputs prevents a full assessment of the company's liquidity position, though no going-concern language is present in the source documents.
Profitability and return metrics are not available in the valuation snapshot, making it difficult to compare the company's performance against industry benchmarks or cohort medians. Without access to key financial ratios such as ROIC or EBITDA margins, an assessment of operational efficiency and capital returns is not possible at this time.
The company's revenue concentration by segment or geography is not disclosed in the available data, limiting the ability to assess exposure to specific markets or product lines. This lack of segmentation data also prevents a detailed evaluation of growth drivers or potential vulnerabilities in the business model.
Growth trajectory data is not available in the outlook section, and historical revenue data is insufficient to determine whether the company is expanding or contracting. The absence of forward-looking guidance or numeric deltas for the current and next fiscal years further limits the ability to project future performance.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet inputs. The company is currently flagged for liquidity risk, though the severity is not quantified. Dilution risk is assessed as low, with no evidence of dilutive instruments or recent equity issuances that would impact shareholder value.
Recent events, including filings or transcripts, are not available in the provided data, preventing an analysis of management commentary, strategic shifts, or regulatory developments that could impact the company's operations or valuation.
Key takeaways
- The company has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
- Liquidity risk cannot be assessed due to missing balance-sheet inputs, though no going-concern language is present in the source documents.
- Profitability and return metrics are not available, making it difficult to compare the company's performance against industry benchmarks.
- Revenue concentration by segment or geography is not disclosed, limiting the ability to assess exposure to specific markets or product lines.
- Growth trajectory data is not available, and historical revenue data is insufficient to determine whether the company is expanding or contracting.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation FY
Market price
$0,20
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Orthopaedic Devices & Implants—
low · business_description · 2026-07-03
Surgical Instruments & Equipment—
low · business_description · 2026-07-03
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Customers1
ANON:CUST:CARL.O:P10ANON:CUST:CARL.O:P10Customer88%Source ↗
Supply chain
Vendors → CARL ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
Peer comparison8 peers · vs CARL · multiples and returns
AB
ABT—
Abbott Laboratories
$107,13
187,2B USDP/E
26,3x
— vs self
Div yield
2,4 %
— vs self
ROE
12,5 %
+72,5 vs self
MD
MDT—
Medtronic PLC
$86,19
110,3B USDP/E
21,4x
— vs self
Div yield
3,4 %
— vs self
ROE
9,7 %
+69,7 vs self
MD
MDLN—
MEDLINE INC.
$40,47
53,2B USDP/E
202,6x
— vs self
Div yield
—
— vs self
ROE
—
— vs self
SY
SYK—
Stryker Corp
$341,20
131,8B USDP/E
38,0x
— vs self
Div yield
—
— vs self
ROE
13,5 %
+73,5 vs self
BD
BDX—
Becton Dickinson And Co
$170,21
48,4B USDP/E
25,6x
— vs self
Div yield
2,8 %
— vs self
ROE
7,0 %
+66,9 vs self
HS
HSIC—
Henry Schein Inc
$88,21
10,1B USDP/E
80,5x
— vs self
Div yield
—
— vs self
ROE
3,0 %
+62,9 vs self
BA
BAX—
Baxter International Inc
$28,10
14,5B USDP/E
—
— vs self
Div yield
2,3 %
— vs self
ROE
-15,4 %
+44,5 vs self
SO
SOLV—
SOLVENTUM CORPORATION
$76,83
13,3B USDP/E
8,6x
— vs self
Div yield
—
— vs self
ROE
30,8 %
+90,8 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,58
Predicted surprise
+0,00
Beat probability
45 %
Analysts
5
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$17,00
Mean$19,00
Median$18,00
High$23,00
Spot$0,20
+9643.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 391 686 sh3 exercises1 insiders
- Director, CEO, President · Stock Option (Right to Buy) → Common StockDisposed 160 567 @ $0,34exercise · 2026-03-03
- Director, CEO, President · Stock Option (Right to Buy) → Common StockDisposed 33 264 @ $4,35exercise · 2026-03-03
- Director, CEO, President · Stock Option (Right to Buy) → Common StockDisposed 197 855 @ $0,34exercise · 2026-03-02
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- Carlo Rino Group Bhd Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$11M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 1 sellsnet -$2,6M8 insiders · last 365d
- Director · Common StockOther 13 698 · 2026-06-03
- Director · Common StockOther 13 698 · 2026-06-03
- Director · Common StockOther 13 698 · 2026-06-03
- Director · Common StockOther 13 698 · 2026-06-03
- Director, CEO, President · Common StockOther 160 567 @ $0,34$54K · 2026-03-03
- Director, CEO, President · Common StockOther 33 264 @ $4,35$145K · 2026-03-03
- Director, CEO, President · Common StockOther 197 855 @ $0,34$66K · 2026-03-02
- Director, CEO, President · Common StockSold 197 855 @ $13,29$2,6M · 2026-03-02
- Chief Commercial Officer · Common StockOther 44 977 · 2026-01-28
- Director, Chief IP Officer · Common StockOther 44 977 · 2026-01-28
- Director, CEO, President · Common StockOther 117 316 · 2026-01-28
- CFO, Treasurer · Common StockOther 44 977 · 2026-01-28
Short positioning
1.4Mshares short+3.4% vs prior
6.58days to cover
27.9%short of daily vol
697fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CARL.KLCanonical
Bursa Malaysia · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Relationship graph
This companySectorCustomers
Evidence & claims
From filings & derived data- Return on assets (FY 2025-12-31): -22.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 256.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 113.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 75.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 65.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 65.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 89.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -13.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -26.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 19.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 240.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 151.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 19.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.32xDerived (calculated)
- Current ratio (FY 2025-12-31): 8.87xDerived (calculated)
- Return on equity (FY 2025-12-31): -30.0%Derived (calculated)
- Current assets (annual): USD 126.67MSEC XBRL filing
- Total liabilities (annual): USD 31.25MSEC XBRL filing
- Long-term debt (annual): USD 15.35MSEC XBRL filing
- Total operating expenses (annual): USD 68.61MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-03 00:00 UTCINSIDER4 insider transactions — 2026-06
2026-06-03INSIDERSidow Kevin transacted 13.7k sh — Director
2026-06-03INSIDEROBOYLE KEVIN C transacted 13.7k sh — Director
2026-06-03INSIDERROOT JONATHAN D transacted 13.7k sh — Director
2026-06-03INSIDERYOUNG PHILIP M transacted 13.7k sh — Director
2026-03-03 00:00 UTCINSIDER7 insider transactions — 2026-03 · net sell $2.4M 3 derivative
2026-03-03INSIDERCordonnier Michael transacted 160.6k sh — Director, CEO, President ~$54k
2026-03-03INSIDERCordonnier Michael transacted 33.3k sh — Director, CEO, President ~$145k
2026-03-03INSIDERCordonnier Michael disposed of 33.3k sh Stock Option (Right to Buy) — Director, CEO, President
2026-03-03INSIDERCordonnier Michael disposed of 160.6k sh Stock Option (Right to Buy) — Director, CEO, President
2026-03-02INSIDERCordonnier Michael transacted 197.9k sh — Director, CEO, President ~$66k
2026-03-02INSIDERCordonnier Michael sold 197.9k sh — Director, CEO, President ~$2.63M
2026-03-02INSIDERCordonnier Michael disposed of 197.9k sh Stock Option (Right to Buy) — Director, CEO, President
2026-01-28 00:00 UTCINSIDER4 insider transactions — 2026-01
2026-01-28INSIDERDurall William Scott transacted 45.0k sh — Chief Commercial Officer
2026-01-28INSIDERCasey Niall transacted 45.0k sh — Director, Chief IP Officer
2026-01-28INSIDERCordonnier Michael transacted 117.3k sh — Director, CEO, President
2026-01-28INSIDERGreenstein Leonard M. transacted 45.0k sh — CFO, Treasurer
2025-07-24 00:00 UTCINSIDER62 insider transactions — 2025-07 · net buy $48.1M 28 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage